Telix Pharmaceuticals (ASX:TLX) has opened a major facility in North Melbourne that brings radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging together under one roof.
The new Telix Manufacturing Solutions North Melbourne site is described by the company as a first of its kind in Australia. It is intended to shorten the pathway from early-stage trials to broader patient access by linking research, clinical trials and treatment in a single location.
Patient care and research at the site will be delivered by the Melbourne Theranostic Innovation Centre, led by Professor Rod Hicks.
The collaboration will cover Telix-sponsored studies, investigator-initiated trials and select third-party work, and the centre will support training in nuclear medicine, radiochemistry, engineering and clinical research to help build the specialist workforce the sector needs.
Dr Christian Behrenbruch, Telix Managing Director and Group CEO, said, “Radiopharmaceuticals are fast becoming an important part of cancer care, but manufacturing capacity for novel treatments, which needs to be near patients, remains a constraint in Australia. This facility will allow us to move new treatments from research into the clinic and patient use more efficiently. It is also an investment in Australia’s sovereign manufacturing capability and the specialist workforce needed to build a globally competitive radiopharmaceutical industry.”
Professor Hicks added, “Bringing these capabilities together will give clinicians faster access to novel radiopharmaceuticals and allow emerging technologies to be assessed in a real-world clinical setting. It will help us select patients more precisely, measure treatment response and generate evidence more quickly as we evaluate new targets and next-generation isotopes and treatment approaches.”
Telix says the facility supports the growth of radiopharmaceuticals that can reveal tumour location on scans and deliver therapeutic radiation directly to cancer cells, which the company describes as an emerging sixth pillar of cancer care alongside surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.
